Igovomab
As of the edition of 20 October 2026, Igovomab is an antibody: withdrawn from the market; acts on MUC16.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market
- Kind
- Antibody
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MUC16 | Mucin-16 | Q8WXI7 |